RLMD - Relmada Therapeutics, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Coral Gables,
United States
Type: Equity
RLMD price evolution
RLMD
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $2.09 | $1.34 | $4.09 | |
| Short term investments | $68.35 | $82.28 | $92.23 | |
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $55.7 | $70.97 | $84.37 | $97.51 |
| Long term investments | ||||
| Property, plant & equipment | ||||
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $0.05 | $0.04 | $0.04 | |
| Total investments | $68.35 | $82.28 | $92.23 | |
| Total assets | $55.72 | $71.03 | $84.41 | $97.55 |
| Current liabilities | ||||
| Accounts payable | $2.35 | $4.17 | $5.19 | $3.51 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $8.1 | $9.54 | $12.36 | $12.19 |
| Long term debt | ||||
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $8.1 | $9.54 | $12.36 | $12.19 |
| Shareholders' equity | ||||
| Retained earnings | -$622.22 | -$600.5 | -$582.73 | -$560.9 |
| Other shareholder equity | ||||
| Total shareholder equity | $61.49 | $72.05 | $85.36 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $4.09 | $5.4 | $44.44 | $2.5 |
| Short term investments | $92.23 | $142.93 | $167.47 | $114.6 |
| Net receivables | $0.51 | $0.09 | $0.17 | |
| Inventory | ||||
| Total current assets | $97.51 | $152.87 | $223.3 | $118.07 |
| Long term investments | ||||
| Property, plant & equipment | $0 | |||
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $0.04 | $0.03 | $0.03 | $0.11 |
| Total investments | $92.23 | $142.93 | $167.47 | $114.6 |
| Total assets | $97.55 | $152.91 | $223.33 | $118.19 |
| Current liabilities | ||||
| Accounts payable | $3.51 | $5.26 | $11.19 | $8.35 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $12.19 | $12.47 | $15.06 | $12.6 |
| Long term debt | ||||
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $12.19 | $12.47 | $15.06 | $12.6 |
| Shareholders' equity | ||||
| Retained earnings | -$560.9 | -$462.11 | -$305.07 | -$179.32 |
| Other shareholder equity | ||||
| Total shareholder equity | $85.36 | $140.44 | $208.26 | $105.58 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $10.72 | $13.31 | $14.75 | |
| Selling, general & administrative | $8.1 | $9.68 | $12.08 | |
| Total operating expenses | $23.01 | $18.82 | $22.99 | $26.83 |
| Operating income | -$18.82 | -$22.99 | -$26.83 | |
| Income from continuing operations | ||||
| EBIT | -$17.77 | -$21.83 | -$25.17 | |
| Income tax expense | ||||
| Interest expense | $1.28 | |||
| Net income | ||||
| Net income | -$21.73 | -$17.77 | -$21.83 | -$25.17 |
| Income (for common shares) | -$17.77 | -$21.83 | -$25.17 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $54.81 | $113.32 | $90.62 | $35.97 |
| Selling, general & administrative | $48.89 | $47.93 | $35.08 | $24.87 |
| Total operating expenses | $103.7 | $161.25 | $125.7 | $60.84 |
| Operating income | -$103.7 | -$161.25 | -$125.7 | -$60.84 |
| Income from continuing operations | ||||
| EBIT | -$98.79 | -$157.04 | -$125.75 | -$58.06 |
| Income tax expense | ||||
| Interest expense | $1.4 | |||
| Net income | ||||
| Net income | -$98.79 | -$157.04 | -$125.75 | -$59.46 |
| Income (for common shares) | -$98.79 | -$157.04 | -$125.75 | -$59.46 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$17.77 | -$21.83 | -$25.17 | |
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | $7.21 | $8.3 | $9.89 | |
| Total cash flows from operations | -$13.26 | -$13.04 | -$10.25 | |
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | $14.01 | $10.06 | $7.74 | |
| Total cash flows from investing | $40.22 | $14.01 | $10.06 | $7.74 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.25 | |||
| Net borrowings | ||||
| Total cash flows from financing | $0.13 | $0.22 | -$0.1 | |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$2.61 | $0.75 | -$2.76 | -$2.61 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$98.79 | -$157.04 | -$125.75 | -$59.46 |
| Operating activities | ||||
| Depreciation | $0 | $0 | ||
| Business acquisitions & disposals | ||||
| Stock-based compensation | $43.81 | $44.19 | $40.49 | $20.78 |
| Total cash flows from operations | -$51.66 | -$103.8 | -$91.87 | -$27.81 |
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | $50.45 | $19.73 | -$54.12 | -$34.45 |
| Total cash flows from investing | $50.45 | $19.73 | -$54.12 | -$34.45 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $43.43 | $185.31 | $20.53 | |
| Net borrowings | -$0.11 | |||
| Total cash flows from financing | -$0.1 | $45.02 | $187.94 | $28.47 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$1.3 | -$39.05 | $41.95 | -$33.78 |
News
Fundamentals
| Market cap | $63.37M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 30.17M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$86.49M |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | -0.73 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$2.87 |
|---|---|
| ROA | -112.06% |
| ROE | N/A |
| Debt/Equity | 0.14 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 6.88 |
| Quick ratio | N/A |